Abstract 3310
Background
Circulating tumor DNA (ctDNA) is a minimally-invasive technique to profile the tumor genome in different cancers but is still underexplored in squamous cell carcinoma of the head and neck (SCCHN). Our aim was to study the relevance of mutational profiling through liquid biopsy in SCCHN.
Methods
We collected plasma cell-free DNA from 39 patients (pts) with locoregional recurrent (LR) (n = 19) and/or metastatic (M) (n = 20) SCCHN. Targeted next-generation sequencing (Illumina, HiSeq4000) was performed on a custom panel of 604 genes (median coverage 1000x). When available (n = 18), a tumor biopsy was sequenced to evaluate the concordance of somatic mutations.
Results
M SCCHN pts had a higher probability of carrying ctDNA than LR pts (70% vs 31%, p = 0.0256). When ctDNA was detected, the quantity (estimated using the median of the allele frequencies (AF) of all the somatic plasma variants) did not differ between the two groups (median 2.3% vs 2.6%, p = 0.97). The concordance between liquid and solid biopsy showed that 26% of the plasma variants (14/54) were not detected in the matched tumors, reflecting some tumor heterogeneity. Conversely, 81% of the variants (168/208) identified in the solid tumors were not detected in the plasma. In a logistic regression model, the detection of the variant in the plasma was related to the metastatic status (Odds Ratio (OR) 4.50, p = 0.012), the variant AF in the tumor (OR = 5.31, p < 0.001) and the ctDNA quantity (OR = 4.13, p < 0.001). Classification of the variant as a driver or passenger based on TCGA and COSMIC was however not relevant (OR = 1.05, p = 0.948). As expected, TP53 was the most frequently mutated gene, both in liquid and solid biopsy. Of clinical interest, the plasma of 3 pts for whom no tumor was available carried 3 different potentially actionable PIK3CA mutations, including the hotspot E545K.
Conclusions
Detection of ctDNA using targeted NGS is feasible in pts with SCCHN, essentially for metastatic disease. Liquid biopsy alone can identify potentially actionable alterations but does not reflect the full landscape of the solid tumor. Presence of a solid tumor variant in the plasma is related to the variant AF, the metastatic status and the ctDNA quantity of the sample.
Clinical trial identification
NCT02139020.
Editorial acknowledgement
Legal entity responsible for the study
Cliniques Universitaires Saint-Luc - Université Catholique de Louvain, Brussels, Belgium.
Funding
Région Wallonne, Belgium - Fondation Louvain UCLouvain.
Disclosure
R. Galot: Advisory / Consultancy: Innate Pharma; Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Amgen. J. Machiels: Honoraria (institution), Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (institution), Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Innate Pharma; Honoraria (institution), Research grant / Funding (institution): Merck Serono; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (institution), Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (institution), Research grant / Funding (institution): Novartis; Honoraria (institution), Research grant / Funding (institution): Janssen; Honoraria (institution), Research grant / Funding (institution): Incyte; Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Research grant / Funding (institution), Travel / Accommodation / Expenses, Uncompensated advisory role: MSD; Advisory / Consultancy, Data safety monitoring board with honoraria: Debio; Advisory / Consultancy, Data safety monitoring board with honoraria: Nanobiotix; Non-remunerated activity/ies, investigator and study coordinator: EORTC. All other authors have declared no conflicts of interest.
Resources from the same session
3361 - Providing a nurse-led telephone intervention for patients treated with oral anticancer medication: symptom management and adherence monitoring
Presenter: Etienne Minvielle
Session: Poster Display session 3
Resources:
Abstract
3937 - Chronological evaluation of health-related quality of life and physical symptoms in postoperative pancreatic cancer patients up to 12 months
Presenter: Naoko Sato
Session: Poster Display session 3
Resources:
Abstract
5620 - Understanding the patients’ Experiences of Radiation Therapy: A Qualitative Study on Prostate Cancer Patients
Presenter: Sakarias Johansson
Session: Poster Display session 3
Resources:
Abstract
1792 - Effect of Kegel exercises on prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy
Presenter: Aydan Uravylioglu
Session: Poster Display session 3
Resources:
Abstract
2169 - The Meaning of Responsibility – a Secondary Analysis of Patients and Caregivers Calls to an Oncology Emergency Telephone
Presenter: Heidi Jacobsen
Session: Poster Display session 3
Resources:
Abstract
4587 - Cognitive function changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Elif Dil
Session: Poster Display session 3
Resources:
Abstract
1981 - Prevention of dental complications in patients with multiple myeloma (MM) receiving bisphosphonates treatment
Presenter: CESCA PUIGMARTI
Session: Poster Display session 3
Resources:
Abstract
2725 - Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients.
Presenter: Marina Bosch - Damas
Session: Poster Display session 3
Resources:
Abstract
5112 - Symptomatic and toxicity management of cancer patients using a telephone support model led by the oncology nurse
Presenter: Gemma Simó
Session: Poster Display session 3
Resources:
Abstract
1365 - Symptom cluster of fatigue, sleep disturbance and depression and its impact on quality of life among Chinese breast cancer patients undergoing adjuvant chemotherapy: A cross-sectional study
Presenter: Xiaole HE
Session: Poster Display session 3
Resources:
Abstract